FAQ Library

FAQ Library published on October 11, 2017
Join Dr. Lonial as he gives a concise summary of Bcl-2 directed treatment as a biomarker-driven therapy in myeloma.
FAQ Library published on September 20, 2017
Dr. Orlowski discusses the major side effects associated with the daratumumab, bortezomib and dexamethasone regimen, and how to manage them.
FAQ Library published on September 6, 2017
Join Dr. Orlowski as he explains the major toxicities associated with the daratumumab, lenalidomide, and dexamethasone regimen, and how to manage these adverse events.
FAQ Library published on August 9, 2017
Join Dr. McCarthy as he discusses which patients are likely to have a very fulminant or aggressive relapse, and how to risk-stratify these patients from diagnosis to prognosis.
FAQ Library published on July 26, 2017
Join Dr. Nooka as he explains how to manage patients who are experiencing adverse events with the two approved monoclonal antibodies, elotuzumab and daratumumab.
FAQ Library published on July 19, 2017
Join Dr. Nooka as he explains how to manage a patient who is experiencing adverse events with the only approved HDAC inhibitor, panobinostat.
FAQ Library published on July 12, 2017
Join Dr. Nooka as he explains how to manage patients who are experiencing adverse events with the three approved proteasome inhibitors, carfilzomib, bortezomib, and ixazomib.
FAQ Library published on July 5, 2017
Join Dr. Nooka as he explains how to manage a patient who is experiencing adverse events with immunomodulatory agents.
FAQ Library published on June 28, 2017
Dr. Philip McCarthy discusses which patients are transplant-eligible and what factors may limit their options.
FAQ Library published on June 14, 2017
Dr. Nooka discusses the crucial steps in identifying if your myeloma patient with cardiac history should receive carfilzomib and if so, when.
Page 1 of 12
Results 1 - 10 of 117